Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated January 4, 2023, reports on a material definitive agreement entered into by Cellectis S.A. on December 28, 2022. The Company is a biopharmaceutical firm focused on gene-edited allogeneic cell therapy candidates for oncology indications.
Key Financial Metrics and Agreement Terms
The filing details a finance contract with the European Investment Bank (EIB) for up to €40.0 million in loans to support R&D activities. The filing does not provide current revenue, profit, cash flow, or existing debt levels.
- Total Loan Capacity: €40.0 million, structured in three tranches.
- Tranche A: €20.0 million at 8.0% annual interest (paid in kind/capitalized).
- Tranche B: €15.0 million at 7.0% annual interest (paid in kind/capitalized).
- Tranche C: €5.0 million at 6.0% annual interest (paid in kind/capitalized).
- Maturity: Six years from the respective disbursement date of each tranche.
- Guarantees: Obligations are guaranteed by material subsidiaries (excluding Calyxt, Inc.).
Material Changes and Conditions Precedent
The agreement represents a new source of potential debt financing. Disbursement of funds is not automatic and is subject to strict conditions precedent for each tranche:
- Tranche A Conditions: Issuance of warrants, satisfaction of arrangement fees, and a specified clinical milestone by a Company licensee.
- Tranche B Conditions: Full drawdown of Tranche A, issuance of warrants, and receipt of at least €20.0 million in cash injections (via equity or subordinated securities) and €15.0 million in partnership payments post-October 31, 2022. Additionally, at least two clinical trials must be actively recruiting with no more than one under mandatory hold.
- Tranche C Conditions: Full drawdown of Tranche B, issuance of warrants, and receipt of at least €25.0 million in cash injections and €25.0 million in partnership payments post-October 31, 2022. Requires at least two active trials (one pivotal or two expansion phase) and no more than one trial under mandatory hold.
- Expiration: Undisbursed funds will be cancelled 36 months after contract execution.
Equity Dilution, Risks, and Covenants
The Company agreed to issue warrants to the EIB as a condition for funding. The number of warrants is calculated based on the 5-day average share price prior to issuance, with specific multipliers and caps (e.g., Tranche A warrants capped at 5% of outstanding shares). The exercise price is set at 99% of the weighted average share price. Warrants include anti-dilution protections and a put option capped at the aggregate principal amount disbursed.
Risks and Covenants:
- Mandatory Prepayment: Triggered by reductions in R&D costs exceeding limits, voluntary prepayment of other debt, change of control, or changes in law rendering performance unlawful.
- Restrictions: Negative covenants restrict asset dispositions, mergers, acquisitions, additional indebtedness, dividends, and share repurchases.
- Default: Includes payment defaults, cross-defaults, material adverse changes, and insolvency events, allowing EIB to demand immediate repayment.
Investor Verification Checklist
- Verify the status of the clinical milestone required for Tranche A disbursement.
- Confirm whether the Company has secured the required €20.0 million cash injection and €15.0 million in partnership payments needed for Tranche B.
- Review the definitive Warrant Agreement terms once negotiated to assess final dilution impact.
- Monitor the status of clinical trial recruitment and any mandatory holds affecting Tranche B and C eligibility.
- Assess the impact of the negative covenants on the Company's ability to pursue strategic transactions or additional financing.